Share Name Share Symbol Market Type Share ISIN Share Description
Physiomics Plc LSE:PYC London Ordinary Share GB00BDR6W943 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.275p -3.89% 6.80p 6.70p 6.90p 7.25p 6.80p 7.075p 1,184,384 15:56:11
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.2 -0.5 -0.8 - 4.00

Physiomics Share Discussion Threads

Showing 24201 to 24220 of 24225 messages
Chat Pages: 969  968  967  966  965  964  963  962  961  960  959  958  Older
DateSubjectAuthorDiscuss
17/2/2018
18:16
Expains your posting, on shift with nothing to do........ but waffle on and on and on and on and on, yawn....
zebbo
16/2/2018
16:30
No the other blues were buys and not delayed - see the trade timestamps.
on target
16/2/2018
16:08
So the other blues could be sells as well. Going down on buys???
spacedust
16/2/2018
15:48
The 200k looks like a sell from 1hr ago.
on target
16/2/2018
15:39
Surprised no tick ups after those buys especially the 200k
spacedust
16/2/2018
11:42
GREAT to see this ! Dr Jim Millen has already transformed Physiomics with 3 THREE Major Pharma contracts in 3 Months But he isn't resting on his laurels... He's going to be hard at in April presenting at Glaxo/Lilly sponsored BioTrinity Conference hTtps://www.biotrinity.com/biolaunchpad
the stigologist
16/2/2018
11:21
Update next week maybe - It's due
cool hand kev
16/2/2018
10:02
That interview is a must read for PYC Investors 'From an academic nicety to an industrial necessity' That is why PYC is going from the odd £30-50k contracts to multi-year repeatable £500k contracts. Domino Theory. htTps://twitter.com/Stockonomist/status/964439061409787904
the stigologist
16/2/2018
09:55
Here is a good interview with Certara's Chief Scientific Officer who was the guy behind their Physiomics-like SimCyp business. 15 February 2018 09:14 In our first interview of 2018 we speak with Professor Amin Rostami, PharmD, PhD, who is a member of BioIVT's new Scientific Advisory Board. Rostami is also Professor of Systems Pharmacology and co-director of the Centre for Applied Pharmacokinetic Research at the University of Manchester, UK, and Certara's chief scientific officer. hTtps://www.epmmagazine.com/opinion/meet-the-maker-epm-talks-to-professor-amin-rostami/ What has been your biggest achievement? Building such confidence in physiological-based pharmacokinetic (PBPK) in vitro in vivo extrapolation among pharmaceutical companies and global regulatory agencies that the discipline progressed from an academic nicety to an industrial necessity. In fact, last year both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) issued guidance on PBPK, which means it is now also a regulatory requirement. One of the reasons that this approach has been so successful is that we worked with the end users of our product from the beginning. In fact, it was part of the business model for the Simcyp Consortium that we created, which is one of the longest-standing consortia and now includes 70% of the world’s big pharma. I am also very proud of having been recognised by ISI as one of the world’s most highly-cited researchers in pharmacology and toxicology. It shows that I’m working in an area that matters to people. I’m also working in an environment where I am surrounded by the best talent, the most able students, post-docs, mentors and, last but not least, peers on scientific advisory boards (SABs) of various companies who seek my advice. I learn from those people tremendously. That’s why I am proud to be part of the BioIVT SAB. They are very high-calibre people who are sitting there and I'm very proud to be a party to that.
the stigologist
16/2/2018
09:46
Key Market Movements: An increasing demand for biosimulation techniques owing to its benefits of predicting the success rate of a drug in development and thereby reduction in cost and time incorporated in trials. Biosimulation has a major role in the development of pediatric drugs wherein there are strict laws to carry out clinical trials. Biosimulation could predict the safety and efficacy of the drug. The incorporation of model-based drug development would reduce drug failures and increase the number of potential drugs in the market in a shorter duration of time. These technologies require skilled expertise to carry out model-based analysis for accurate results. Market Insights The biosimulation market is expected to show remunerative growth in the forecast period of 2017-2025. Biosimulation also known as ‘modeling and simulation’, or ‘model-based drug development’ or ‘in silico drug development’ is a technique which uses computer based programs for simulation of biologic process, thus capturing biological elements and their relationships, and simulating the behavior of a certain system in different situations. The cost of developing a new drug is enormous and an exorbitant amount of money and time is incorporated for the development by the pharmaceutical industries and research institutes. According to a 2014 study by the Tufts Center for the Study of Drug Development (TCSDD), the cost of developing a new drug considering from its R&D to marketing approval accounts to around $2.9 billion per NDA. The drug development is always not a success in the market and also faces drug failures which may occur at any stage of development which effects the growth of the pharmaceutical industry. For e.g. Bristol-Mayer Squibb faced 35% drop in its share price post its phase 3 failure of cancer immunotherapy drug Opdivo. To avoid such drug failures and minimalize the utilization of time, money and patients, biosimulation techniques are utilized. According to an article posted by Certara, Inc., incorporating biosimulation/model-based drug development accounts to $97 million of savings per NDA. Biosimulation is used for lead identification and optimization, target identification and optimization, pre-clinical trials, clinical trials and regulatory approvals. Biosimulation technique helps in predicting the success rate of a drug and its potential to gain market approval which would help the industries to strategize accordingly and economize their revenue. Moreover, it also monitors the resources incurred by initially assessing for any drug-drug interactions, avoid ethical issues of unnecessary trials, eliminate the need for some clinical trials & design safer and efficient trials. It would predict the number of patients required for the study thus reducing the cost incurred on patients and increase the success rate of a New Drug Application (NDA). Owing to the aforementioned benefits of biosimulation and the current markets requirement of more efficacious drugs, reduced drug failure rate and decreased cost and time for drug development is driving the biosimulation market. North America is held a largest share in the biosimulation market. An increase in drug development, stringent regulatory policies ensuring patient safety and efficacy standards, rising number of strategic collaborations amongst pharmaceutical industries/research institute with in silico software developers for model-based drug development are the major factors that increases the demand in this market. Asia-Pacific is expected to witness highest growth in the biosimulation market during the forecast period, 2017-2025 owing to increasing presence of CRO’s, rising healthcare infrastructure, developing healthcare IT and an extensive presence of research and development activities. htTps://industrytoday.co.uk/pharmaceutical/biosimulation-market-is-expected-to-reach-us--4-12-bn-by-2025---credence-research
the stigologist
16/2/2018
09:44
Drug designing tools are software and databases that are used at an early stage of modern drug discovery process. The use of computers and computational tools have permeated all aspects of drug-discovery and have formed essential part of structure-based drug design. Drug discovery and development is tremendous lengthy process involving multiple disciplines such as chemistry, biology, biophysics, structural biology and computational science. Typical drug discovery starts with target identification, lead discovery & optimization, pre-clinical in vitro and in vivo studies involving approximately 12 to 14 years and costs up to US$ 1.2 to 1.4 Bn. However, in silico screening of chemical database has now become the important tool to reduce the time, cost and chances of failure of lead at later stage of development. Computer aided drug designing or in silicodrug designing has gained significant momentum in past 3 decades. There are different techniques used in in silico drug designing and including visualization, molecular dynamics simulation, homology, energy minimization tools, molecular docking etc. drug discovery tools can be used in all stages of drug development including discovery pre-clinical and clinical stage. Today all pharmaceutical and biotechnology companies take the advent of drug designing tools to cut down the time and resources required in drug development process and modern drug discovery is almost impossible without the use of computational tools. Thus market for drug designing tools is ever growing with rapid technological advancements developments. The primary factor driving the growth of global drug designing tools market is increasing pace of research and development in all verticals of pharmaceutical, biotechnology and life science industries. Moreover, immediate need of medicines to treat chronic diseases such as cancer, diabetes, etc., increasing complexity of drug discovery due to huge amount of biological data, need for simplified ways to handle big data generated during drug discovery process, growing stringency in regulations for animal handling, etc. are some others factors fueling the demand for drug designing tools. The only factors hampering the growth of global drug designing tools market are high cost of such tools and lack of skilled professionals to operate the tools.
the stigologist
16/2/2018
09:26
A company mentioned by Hybridan in their Initiation of Coverage research note on Physiomics is Simulations Plus. (NASDAQ:SLP) Simulations Plus is valued at c. $280m and has annual revenue about $20m i.e. it is valued at over 10x revenues with growth of c.30% in it's topline Physiomics is growing revenue at c.100% but it's revenues are being valued at sub 10x In fact given Physiomics have the extra growth potential of the Cancer DSS tool it's quite clear its dramatically undervalued What I don't understand is why won't Hybridan mention Certara when it is quite clearly the main comparitor ! $850m Certara e.g. if you google Physiomics and Certara you will find Industry reports on them Biosimulation Market Report 2017-2022: Research Findings ... satPRnews (press release)-11 Feb 2018 Certara(U.S.), Simulation Plus Inc. (U.S.), Dassault Systemes SA (France), Schrodinger Inc. (U.S.), Advanced Chemistry DevelopmentInc. (Canada), Chemical Computing GroupInc. (Canada), Physiomics PLC (U.K.), Entelos Holding Corporation (U.S.), Rhenovia Pharma Ltd. (France), Genedata AG (Switzerland), And Others.
the stigologist
16/2/2018
09:08
Ex Founder of Physiomics (PYC) Peter Hoskins who writes on ADVFN as "ant15" ant15 - 30 Nov 2017 - 15:07:26 - 3710 of 4892 Writing as a Founder of Physiomics I am a shareholder but do not represent the company in any capacity. WHY THIS SHARE IS WORTH A £1.00 giving it a market cap of still less than £60.million *It is first to market *Scarcity of trained personnel in what is still an emergent technology ( there are currently over a 1000 vacancies to be filled in this sector and few trained personnel ) *The development time needed to populate models and most importantly the availability of patient data that needs to be accessed apart from what is available in the literature is protracted PYC has been through this curve perfecting its models over time. * The Biometric Grant serves to demonstrate not only the faith in the company but also underpins the access PYC is being given to Patient data In this case in the field of Oesophgeal Cancer *Collaborations with major pharmas have been constrained whilst the models are perfected and due to the secretive nature of all pharmas who generally speaking do not want to share data. The latest contract has dramatically increased the visibility of what PYC do and do best and will encourage a raft of Biotech analysts to write it up as more contracts are announced *PYC's Cardiac Toxicity Model is 50% plus better than any other available on the market Why is this important? it is the major cause of attrition in clinical trials ( drug failure ) *The cost savings PYC is able to realise for major Pharma is key and further to small Biotechnology companies whose funding is limited as they try to move molecules into clinical trials. * Big Pharmas feed their development pipelines by acquiring or licensing in small bio's however these sales have moved progressively from Targets 20 years ago to IND candidates and onto Phase 1/2 putting the burden of proof onto the small Bio Techs who need to conserve and raise cash ( not easy and never has been ) *In 2010 Scientific American stated the cost of Development of a drug from start to finish FDA approval was $1.4 billion...In 2016 Association of British Pharmaceutical Industry Has upped this to £1.5 billion ( sterling) a really significant increase. NOTING that only 1 in 5000 drugs get final approval and this is not factored into the costs as above as representing only a successful transition of 1 drug to approval *In America alone $12-%14 billion per year is spent on Animal Testing Robert Solari a senior research fellow at Imperial College states "The predictive power of biology in reseach is relatively poor in research labs" and notes that the efficacy of animal testing are not particulary predictive of Human Efficacy PYC is "in Silico" ( in computer) its accuracy is one of its major plus points * PYC is striving to personalised medicine The HOLY GRAIL with tremendous Social and Financial Implications. * Sooner rather than later The FDA in America will have to recognise that rational drugs designed in computers can be tested in them too saving countless millions of development costs and most importantly time taken to approval ie move from the 20 to the 21st century * PYC has taken time to develop its excellent technology I believe I have cited the reasons for its true value. It has been challenged in recent times but has now become of age an is exceptionally well positioned in a market sector that is set to expand exponentially. To recap A leading British Technology currently way undervalued and one that is not a speculative BUY It has proven technology in a burgeoning sector and might well become the focus of an acquisition target as it is still so undervalued
the stigologist
16/2/2018
08:32
They can issue another 28 million shares. So if they issued the lot a 4p that would give the company a value of £3.4 million. Even that I'm afraid is pushing it considering it was worth only £587k on 27/11/2017. I'm still going for 2p which would give an over generous value of £1.7m.
pwhite73
16/2/2018
08:16
Share issue at 4 pence I predict, they need money in the bank to give assurance to new investors that they are not relying on deals that might or might not come within this year.They already said that the deal with merck only coves 60 percent of this year projected expenses.
naplion
16/2/2018
08:01
Oxford BioMedica has a share price of 12p and market cap of £372m below was an update from the company yesterday https://uk.advfn.com/stock-market/london/oxford-biomedica-OXB/share-news/Oxford-Biomedica-PLC-Bioverativ-Collaboration-and/76723354 "The agreement includes a licence to use OXB's LentiVector Enabled technology and access to its industrial-scale manufacturing technology..... " "Under the terms of the agreement, Oxford BioMedica will receive a $5 million upfront payment from Bioverativ. Oxford BioMedica is also eligible to receive various milestone payments, potentially worth in excess of $100 million, and undisclosed royalties on net sales of Bioverativ's lentiviral vector haemophilia products" That is what real working licensed patent protected technology can do in this industry. Now compare the above to PYC's last update - £70k after 15 years in the business.
pwhite73
15/2/2018
16:46
PWhite73, I had to access the server, to retrieve your “original” post from this morning @ 11.57 GMT ………………………………............................ PWhite73 15 Feb '18 - 11:57 - 1679 "Do you see red ticks everywhere "? You may be suffering from a little known disease called Crimsonitis. We at Healthcare Advance have over 15 years experience of treating patients with this rare but debilitating disease. Why not give us a no obligation call on 0800 778 6745 or email us at http:www. HA/Crimson.org.uk. (Which you later edited to PWhite73 15 Feb '18 - 11:57 - 1679 I've said before I don't red tick anybody. Just what is the point) ………………………………............................. What this clearly demonstrates, (apart from you having the complete set, of root mental afflictions) is that your post last week on 13 Feb is 100% correct PWhite73 - 13 Feb 2018 - 09:02:09 - 1631 of 1678 “Just one another thing Minja19 you are not in my league and I think you are slowly becoming aware of it” ................. 100% correct PWhite, you are undoubtedly in a very special league, completely on your own. FRIENDLY WARNING all your posts are on the server, So before you post in future, I advise you to double check your content, so that at a later stage you don’t feel the need to completely delete your posts, or heavily edit them…… enjoy the rest of your miserable day.
minja19
15/2/2018
14:37
Maybe Physiomics will be called upon by a Pharma to assist. Cancer Research UK has announced that £45 million will be invested into its network of clinical trials units across the UK, one of the charity£s largest investments in clinical research to date. Clinical trials are the only way to find out if a new treatment is safe to use, and if it£s better than existing treatments. Hence, this investment is essential for better future options for patients. hxxps://www.braintumourresearch.org/media/news/news-item/2018/02/15/brain-tumour-research-welcomes-commitment-to-the-funding-of-clinical-trials-for-cancer-treatment
myamay16
15/2/2018
11:57
I've said before I don't red tick anybody. Just what is the point.
pwhite73
15/2/2018
09:10
Ex Founder of Physiomics (PYC) Peter Hoskins who writes on ADVFN as "ant15" ant15 - 30 Nov 2017 - 15:07:26 - 3710 of 4892 Writing as a Founder of Physiomics I am a shareholder but do not represent the company in any capacity. WHY THIS SHARE IS WORTH A £1.00 giving it a market cap of still less than £60.million *It is first to market *Scarcity of trained personnel in what is still an emergent technology ( there are currently over a 1000 vacancies to be filled in this sector and few trained personnel ) *The development time needed to populate models and most importantly the availability of patient data that needs to be accessed apart from what is available in the literature is protracted PYC has been through this curve perfecting its models over time. * The Biometric Grant serves to demonstrate not only the faith in the company but also underpins the access PYC is being given to Patient data In this case in the field of Oesophgeal Cancer *Collaborations with major pharmas have been constrained whilst the models are perfected and due to the secretive nature of all pharmas who generally speaking do not want to share data. The latest contract has dramatically increased the visibility of what PYC do and do best and will encourage a raft of Biotech analysts to write it up as more contracts are announced *PYC's Cardiac Toxicity Model is 50% plus better than any other available on the market Why is this important? it is the major cause of attrition in clinical trials ( drug failure ) *The cost savings PYC is able to realise for major Pharma is key and further to small Biotechnology companies whose funding is limited as they try to move molecules into clinical trials. * Big Pharmas feed their development pipelines by acquiring or licensing in small bio's however these sales have moved progressively from Targets 20 years ago to IND candidates and onto Phase 1/2 putting the burden of proof onto the small Bio Techs who need to conserve and raise cash ( not easy and never has been ) *In 2010 Scientific American stated the cost of Development of a drug from start to finish FDA approval was $1.4 billion...In 2016 Association of British Pharmaceutical Industry Has upped this to £1.5 billion ( sterling) a really significant increase. NOTING that only 1 in 5000 drugs get final approval and this is not factored into the costs as above as representing only a successful transition of 1 drug to approval *In America alone $12-%14 billion per year is spent on Animal Testing Robert Solari a senior research fellow at Imperial College states "The predictive power of biology in reseach is relatively poor in research labs" and notes that the efficacy of animal testing are not particulary predictive of Human Efficacy PYC is "in Silico" ( in computer) its accuracy is one of its major plus points * PYC is striving to personalised medicine The HOLY GRAIL with tremendous Social and Financial Implications. * Sooner rather than later The FDA in America will have to recognise that rational drugs designed in computers can be tested in them too saving countless millions of development costs and most importantly time taken to approval ie move from the 20 to the 21st century * PYC has taken time to develop its excellent technology I believe I have cited the reasons for its true value. It has been challenged in recent times but has now become of age an is exceptionally well positioned in a market sector that is set to expand exponentially. To recap A leading British Technology currently way undervalued and one that is not a speculative BUY It has proven technology in a burgeoning sector and might well become the focus of an acquisition target as it is still so undervalued
the stigologist
Chat Pages: 969  968  967  966  965  964  963  962  961  960  959  958  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180217 21:45:27